DÄ internationalArchive50/2007Epidemiology, Pathophysiology, and Therapy of Calciphylaxis

Review article

Epidemiology, Pathophysiology, and Therapy of Calciphylaxis

Dtsch Arztebl 2007; 104(50): A-3481

Ketteler, M; Biggar, P H; Brandenburg, V M; Schlieper, G; Westenfeld, R; Floege, J

For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.

1. Selye H: The dermatologic implications of stress and calciphylaxis. J Invest Dermatol 1962; 39: 259–75. MEDLINE
2. Coates T, Kirkland GS, Dymock RB, Murphy BF, Brealey JK, Mathew TH, Disney AP: Cutaneous necrosis from calcific uremic arteriolopathy. Am J Kidney Dis 1998; 32: 384–91. MEDLINE
3. Fine A, Zacharias J: Calciphylaxis is usually non-ulcerating: risk factors, outcome and therapy. Kidney Int 2002; 61: 2210–7. MEDLINE
4. Llach F, Velasquez Forero F: Secondary hyperparathyroidism in chronic renal failure: pathogenic and clinical aspects. Am J Kidney Dis 2001; 38(5 Suppl 5): S20–33. MEDLINE
5. Block GA: Control of serum phosphorus: implications for coronary artery calcification and calcific uremic arteriolopathy (calciphylaxis). Curr Opin Nephrol Hypertens 2001; 10: 741–7. MEDLINE
6. Case Report. N Engl J Med 2001; 345: 1119–24. MEDLINE
7. Mazhar AR, Johnson RJ, Gillen D et al.: Risk factors and mortality associated with calciphylaxis in end-stage renal disease. Kidney Int 2001; 60: 324–32. MEDLINE
8. Duffy A, Schurr M, Warner T, Chen H: Long-term outcomes in patients with calciphylaxis from hyperparathyroidism. Ann Surg Oncol 2006; 13: 96–102. MEDLINE
9. Ketteler M, Schlieper G, Floege J: Calcification and cardiovascular health: new insights into an old phenomenon. Hypertension 2006; 47: 1027–34. MEDLINE
10. Murshed M, Schinke T, McKee MD, Karsenty G: Extracellular matrix mineralization is regulated locally; different roles of two Gla-containing proteins. J Cell Biol 2004; 165: 625–30. MEDLINE
11. Luo G, Ducy P, McKee MD, Pinero GJ, Loyer E, Behringer RR, Karsenty G: Spontaneous calcification of arteries and cartilage in mice lacking matrix Gla protein. Nature 1997; 386: 78–81. MEDLINE
12. Price PA, Faus SA, Williamson MK: Warfarin causes rapid calcification of the elastic lamellae in rat arteries and heart valves. Arterioscler Thromb Vasc Biol 1998; 18: 1400–7. MEDLINE
13. Schurgers LJ, Spronk HM, Soute BA, Schiffers PM, Demey JG, Vermeer C: Regression of warfarin-induced medial elastocalcinosis by high intake of vitamin K in rats. Blood 2007; 109: 2823–31. MEDLINE
14. Schurgers LJ, Teunissen KJ, Knapen MH et al.: Novel conformation-specific antibodies against matrix – carboxyglutamic acid (Gla) protein – undercarboxylated matrix Gla protein as marker for vascular calcification. Atheroscler Thromb Vasc Biol 2005; 25: 1629–33. MEDLINE
15. Ketteler M: Fetuin-A and extraosseous calcification in uremia. Curr Opin Nephrol Hypertens 2005; 14: 337–42. MEDLINE
16. Lebreton JP, Joisel F, Raoult JP, Lannuzel B, Rogez JP, Humbert G: Serum concentration of human alpha 2 HS glycoprotein during the inflammatory process: evidence that alpha 2 HS glycoprotein is a negative acute-phase reactant. J Clin Invest 1979; 64: 1118–29. MEDLINE
17. Korkmaz C, Dundar E, Zubaroglu I: Calciphylaxis in a patient with rheumatoid arthritis without renal failure and hyperparathyroidism: the possible role of long-term steroid use and protein S deficiency. Clin Rheumatol 2002; 21: 66–9. MEDLINE
18. Stenvinkel P, Ketteler M, Johnson R et al.: Interleukin-10, IL-6 and TNF-a in end-stage renal disease – the good, the bad and the ugly. Kidney Int 2005; 67: 1216–33. MEDLINE
19. Schäfer C, Heiss A, Schwarz A et al.: The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 2003; 112: 357–66. MEDLINE
20. Ketteler M, Bongartz P, Westenfeld R et al.: Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet 2003; 361: 827–33. MEDLINE
21. Hermans MM, Brandenburg V, Ketteler M et al.: Association of serum fetuin-A levels with mortality in dialysis patients. Kidney Int 2007; 72: 202–7. MEDLINE
22. Velasco N, MacGregor MS, Innes A, MacKay IG: Successful treatment of calciphylaxis with cinacalcet-an alternative to parathyroidectomy? Nephrol Dial Transplant 2006; 21: 1999–2004. MEDLINE
23. Cicone JS, Petronis JB, Embert CD, Spector DA: Successful treatment of calciphylaxis with intravenous sodium thiosulfate. Am J Kidney Dis 2004; 43: 1104–8. MEDLINE
24. Shiraishi N, Kitamura K, Miyoshi T et al.: Successful treatment of a patient with severe calcific uremic arteriolopathy (calciphylaxis) by etidronate disodium. Am J Kidney Dis 2006; 48: 151–4. MEDLINE
25. Basile C, Montanaro A, Masi M, Pati G, De Maio P, Gismondi A: Hyperbaric oxygen therapy for calcific uremic arteriolopathy: a case series. J Nephrol 2002; 15: 676–80. MEDLINE